ReviewHemaSphere2022
Comprehensive Diagnosis and Management of POEMS Syndrome.
Review in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes.Bone marrow transplantation · 2026Article
- POEMS syndrome: A case report.Radiology case reports · 2026Article
- A Rare Case of POEMS-Associated Multicentric Castleman Disease with an Atypical Osteolytic PresentationTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- POEMS syndrome with atypical presentation: A rare case.Journal of postgraduate medicine · 2026Article
- Factors associated with improvement in gait disturbance of polyneuropathy in POEMS syndrome.BMC neurology · 2026Article
- Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma.Blood advances · 2026Article
- Article
- POEMS syndrome with cardiovascular lesions as the initial manifestation: a case report and literature review.Frontiers in cardiovascular medicine · 2026Article
- POEMS syndrome presenting as presumed chronic glomerulonephritis with a 1-year delay in diagnosis: a case report.Frontiers in medicine · 2026Article
- Article
- Article
- Refractory ascites: unveiling POEMS syndrome as the underlying cause: a case report and literature review.Frontiers in medicine · 2025Article
- Monoclonal Gammopathy-Associated Neuropathy.Current hematologic malignancy reports · 2024Review
- POEMS syndrome with undetectable M-protein: a case report and literature review.Diagnostic pathology · 2024Review
- Article
- Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with dilated cardiomyopathy: A case report.World journal of clinical cases · 2024Article
- Pulmonary manifestations of POEM syndrome: a retrospective analysis of 282 cases.BMC pulmonary medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyneuropathy Organomegaly, Endocrinopathy, Monoclonal protein and Skin changes syndrome is a rare multisystem condition with a range of manifestations which are often overlooked as trivial comorbidities, until their whole triggers the possibility of the diagnosis. The diagnosis is typically delayed by 12-16 months, by which time patients can be severely disabled. There are no established consensus guidelines. We provide clinicians a comprehensive blueprint for managing POEMS from diagnostic suspicion through the work-up, selection of therapy, follow-up, and treatment of relapse based on published evidence and our large single-center experience. A multidisciplinary approach is essential including expert hematologists, neurologists, histopathologists, radiologists, and neurophysiologists. The aim of treatment is to eradicate the underlying plasma cell dyscrasia, but there are limited trial data to guide treatment decisions. Supportive care considerations include management of endocrinopathy, neuropathy, thrombosis, and infection. Response assessment is centered on clinical, neuropathy, hematological, vascular endothelial growth factor, and radiological criteria. Future clinical trials are welcomed in this setting where evidence is limited.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.